SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE
Clinical safety rating: safe
Animal studies have demonstrated safety
Sulfacetamide sodium inhibits bacterial dihydropteroate synthase, blocking folate synthesis; prednisolone sodium phosphate suppresses inflammation by binding glucocorticoid receptors, inhibiting phospholipase A2 and pro-inflammatory cytokine production.
| Metabolism | Sulfacetamide is metabolized via hepatic acetylation; prednisolone is primarily metabolized by hepatic CYP3A4. |
| Excretion | Renal excretion of unchanged sulfacetamide (60-75%) and prednisolone metabolites (primarily conjugated); minimal biliary/fecal elimination (<10% for each). |
| Half-life | Sulfacetamide: 6-8 hours (prolonged in renal impairment). Prednisolone: 2-4 hours (terminal half-life). Clinically, systemic effects may persist longer due to tissue distribution. |
| Protein binding | Sulfacetamide: 10-30% bound to albumin. Prednisolone: 70-90% bound to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | Sulfacetamide: Vd ~0.3 L/kg (distributes into extracellular fluid and tissues). Prednisolone: Vd ~0.5-1 L/kg (wide distribution including intracellular compartments). |
| Bioavailability | Topical ophthalmic: Systemic bioavailability negligible (<1% via corneal absorption). Oral/IV not applicable for this fixed combination product. |
| Onset of Action | Topical ophthalmic: Onset of anti-inflammatory and antimicrobial effects within hours; peak effect within 1-2 days with continuous dosing. |
| Duration of Action | Ophthalmic: Duration of anti-inflammatory effect after single dose ~6-12 hours; requires qid or more frequent dosing for sustained effect. Systemic effects negligible at ocular doses. |
| Molecular Weight | 366.4 |
1-2 drops into the conjunctival sac of the affected eye(s) every 2-4 hours during the day and at bedtime; frequency may be decreased as clinical signs improve.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No systematic dosage adjustment is required for ophthalmic use, as systemic absorption is minimal. However, in patients with severe renal impairment, consider potential accumulation of sulfacetamide; monitor for adverse effects. |
| Liver impairment | No dosage adjustment is necessary for ophthalmic use due to negligible systemic absorption. In patients with severe hepatic impairment, use with caution. |
| Pediatric use | Children: 1-2 drops into the conjunctival sac of the affected eye(s) every 2-4 hours during the day and at bedtime; use with caution in infants under 2 months due to possible sulfonamide-related kernicterus risk. |
| Geriatric use | Same as adult dosing; use with caution in elderly patients with concurrent conditions (e.g., glaucoma, dry eye) or those on multiple medications. Monitor for increased intraocular pressure with prolonged steroid use. |
| 1st trimester | Use only if potential benefit justifies potential risk; sulfacetamide may cause kernicterus in neonates, prednisolone associated with cleft palate risk in animal studies. |
| 2nd trimester | Use with caution; monitor for maternal blood pressure changes and fetal growth restriction due to corticosteroid. |
| 3rd trimester | Avoid if possible; sulfonamides can cause kernicterus in newborn, prednisolone may cause neonatal adrenal suppression. |
Clinical note
No significant drug interactions For ophthalmic use only can cause local irritation.
| Placental transfer | Both components cross the placenta; sulfacetamide: some transfer, prednisolone: significant transfer (e.g., 10-15% of maternal levels). |
| Breastfeeding | Sulfacetamide may be excreted in breast milk and could cause kernicterus in infants with G6PD deficiency; prednisolone is present in breast milk in low amounts but caution is advised with high doses. Use only if clearly needed and monitor infant for adverse effects. |
■ FDA Black Box Warning
None
| Common Effects | Stinging |
| Serious Effects |
Hypersensitivity to sulfonamides or prednisoloneSystemic fungal infectionsActive untreated bacterial infectionPremature infants (sulfacetamide)
| Precautions | Prolonged use may lead to secondary ocular infections, Sulfonamide hypersensitivity reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), Elevated intraocular pressure with corticosteroid use, Cataract formation with prolonged corticosteroid use, Corneal thinning or perforation with existing corneal disease, Systemic absorption of both components, especially with prolonged use |
| Food/Dietary | No significant food interactions. Avoid alcohol if it causes stomach upset or drowsiness. No dietary restrictions necessary. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Sulfacetamide, like other sulfonamides, crosses the placenta and may cause teratogenic effects, although risk is low. Prednisolone is a corticosteroid; first-trimester exposure is associated with a small increased risk of oral clefts (odds ratio ~1.3-1.6). Second/third trimester: Sulfacetamide may increase risk of kernicterus in the neonate if used near term due to bilirubin displacement. Prednisolone may cause fetal adrenal suppression, intrauterine growth restriction, and preterm delivery with prolonged high-dose use. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of infection. Assess fetal growth via ultrasound (due to prednisolone). In neonates, observe for jaundice (kernicterus risk from sulfacetamide) and adrenal insufficiency (if maternal prednisolone use was prolonged/high dose). |
| Fertility Effects | Limited human data. Corticosteroids may inhibit ovulation at high doses; sulfacetamide has no known direct effect on fertility. No significant impact expected at standard ophthalmic doses. |
| Clinical Pearls | Combination product for ophthalmic use only. Shake well before instillation. Prescribe for short-term use (7-10 days) to minimize steroid-induced adverse effects. Contraindicated in viral (herpes simplex), fungal, or mycobacterial ocular infections. Monitor intraocular pressure (IOP) after 2 weeks of therapy. Use with caution in patients with glaucoma or corneal thinning. Do not use in patients wearing contact lenses during active infection. |
| Patient Advice | Use only in the eye(s) as directed by your doctor. · Shake the bottle well before each use to mix the medication. · Wash hands before instilling drops. Avoid touching the dropper tip to any surface. · Remove contact lenses before use and wait at least 15 minutes before reinserting. · Do not drive or operate machinery if your vision is blurred after application. · Complete the prescribed course even if symptoms improve; do not use longer than directed. · Report any eye pain, vision changes, or worsening redness to your doctor immediately. |